Helmy Eltoukhy
Helmy Eltoukhy | |
---|---|
Alma mater | Stanford University BS, Electrical engineering MS, Electrical engineering PhD, Electrical engineering Stanford Genome Technology Center (Postdoc) |
Known for | Co-Founder & CEO, Guardant Health Co-Founder & CEO, Avantome |
Spouse | Carson Eltoukhy (? - 2020) |
Scientific career | |
Fields | Genomics Electrical engineering |
Thesis | An integrated system for de novo DNA sequencing |
Doctoral advisor | Abbas El Gamal[1][2] |
Helmy Eltoukhy is an American
Education
Eltoukhy attended
Career
Genome Technology Center
After graduation, Eltoukhy completed a
Avantome and Illumina
In 2007, Eltoukhy and Mostafa Ronaghi co-founded the biotechnology startup company Avantome, to accelerate the commercialization of semiconductor sequencing technologies and affordable high-throughput DNA sequencing.[3][8] Eltoukhy was president and CEO of the new company until 2008, when Avantome was acquired by Illumina.[3][14] As part of the acquisition terms, Ronaghi and Eltoukhy joined Illumina, where Eltoukhy continued pioneering genomic research as director of Advanced Sequencing Development until 2012.[8] At Illumina, Avantome’s CMOS/semiconductor sequencing platform became the basis for Project Firefly, a program to develop an "integrated sequencing solution simple and affordable enough to install in hospitals for routine testing".[3][15] In 2018, Illumina launched iSEQ, a new product developed using Avantome’s CMOS sensor approach combined with nanowell technology; iSEQ delivered on the original Avantome goals of low cost instrumentation and reduced per-sample processing cost in a long read format.[14][16]
Guardant Health
In 2012, Eltoukhy and
Under Eltoukhy’s direction as CEO, Guardant Health raised over one billion dollars (US) in financing,
In 2017, a
Eltoukhy was named to Time Magazine’s inaugural 50 Most Influential People in Healthcare (2018)[42][43] and Fortune’s 40 under 40 (2017).[44][45]
Representative publications
Journal articles
- El Gamal A and Eltoukhy H (2005) CMOS image sensors. IEEE Circuits and Devices Magazine 21(3), 6-20[46]
- Eltoukhy H et al. (2006) A 0.18-/spl mu/m CMOS bioluminescence detection lab-on-chip. IEEE Journal of Solid-State Circuits 41(3)[47]
- Lanman et al. (2015) Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
- Odegaard J et al. (2018) Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. PMID 29691297
- Zill OA et al. (2018) The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. PMID 29776953
Patents
- Engineered luciferases, (2009).[49]
- Biological analysis arrangement and approach therefor, (2012).[50]
- Multibase delivery for long reads in sequencing by synthesis protocols, (2012).[51]
- Methods and systems for detecting genetic variants, (2015).[52]
- Methods to detect rare mutations and copy number variation, (2016).[53]
- Methods for multi-resolution analysis of cell-free nucleic acids, (2017).[54]
Recognition
Eltoukhy was named to Time Magazine’s inaugural 50 Most Influential People in Healthcare in 2018, Fortune’s 40 under 40 in 2017,[44][45] and the San Francisco Business Times 40 under 40 in 2019.[55] He has served as an invited speaker or panelist at the World Economic Forum,[56] Fortune Brainstorm Health 2017,[57] The Business of Personalized Medicine Summit 2018,[58][59] HLTH (healthcare innovation) 2018,[60] and the World Medical Innovation Forum 2016.[61]
References
- ^ a b "Stanford Engineering, Abbas El Gamal - Previous Students". Stanford University. 2019. Retrieved 5 Nov 2019.
- ^ a b c Shinal, John (20 Feb 2015). "More-accurate cancer tests based on computer math". USA Today. Retrieved 5 Nov 2019.
- ^ a b c d Carroll, John (23 Jul 2008). "Illumina snares sequencing tech in $60M buyout". fiercebiotech.com. Questex, LLC. Retrieved 19 Oct 2019.
- ^ a b Hay, Timothy (17 Jul 2015). "Liquid Biopsy the Key to 'Active Surveillance' of Cancer, Guardant Health Says". The Wall Street Journal. USA. Retrieved 18 Oct 2019.
- ISBN 978-1-351-98433-1. Retrieved 19 October 2019.
- ^ a b c Hindery, Robin (2015). "Keeping Pace with Cancer: Helmy Eltoukhy's startup, Guardant Health, is making waves in the healthcare world by using cutting-edge DNA sequencing technology to track cancer in real time". Gentry Health. California, USA: The Golden State Company. pp. 108–109. Retrieved 19 Nov 2019.
- ^ "BellarmineBells". Instagram. Bellarmine College Preparatory. 23 Mar 2016. Retrieved 19 Nov 2019.
- ^ a b c d e "Illumina to Buy Avantome for Up to $60M; Long, Cheap Reads Will Target Sanger". genomeweb.com. 29 Jul 2008.
- OCLC 71209106.
- ISBN 978-0-8194-4766-1. Retrieved 22 October 2019.
- ^ "Human Genome Project Completion: Frequently Asked Questions". genome.gov. National Human Genome Research Institute. Retrieved 22 Oct 2019.
- ^ "NHGRI Seeks Next Generation of Sequencing Technologies". genome.gov. 14 Oct 2004. Retrieved 22 Oct 2019.
Mostafa Ronaghi, Stanford Genome Technology Center, $1.8 million (3 years) "Pyrosequencing Array for DNA Sequencing"
- ^ Ron Kerr, Helmy Eltoukhy, Bambi Francisco (23 Feb 2016). $1,000 is the "right price" for human genome (video). Vator. Retrieved 22 Oct 2019.
- ^ a b "Illumina Unveils Mini Targeted Sequencer, Semiconductor Sequencing Project at JP Morgan Conference". GenomeWeb. USA. 11 Jan 2016. Retrieved 16 Oct 2019.
- ^ "At AGBT, Illumina Provides Additional Details on Project Firefly". genomeweb.com. 12 Feb 2016.
- ^ "Illumina Launches Semiconductor Sequencer, Partners With Thermo Fisher, Releases Prelim Earnings". genomeweb.com. 9 Jan 2018.
- ^ a b Medeiros, Joao (7 Feb 2019). "How SoftBank ate the world: Led by the charismatic Masayoshi Son, Japanese conglomerate SoftBank's Vision Fund is taking over tech, one company at a time. This is the story of what happens if the disruptors are disrupted". Wired. Retrieved 25 Oct 2019.
- ^ a b Leuty, Ron (11 May 2017). "Blood money: Peninsula liquid biopsy company gets $360M injection". San Francisco Business Times. Retrieved 3 Nov 2019.
- ^ a b "Blood-based liquid biopsies are the new frontier in cancer diagnosis". fiercebiotech.com. Questex, LLC. 20 Jul 2015. Retrieved 20 Oct 2019.
- ^ a b c Cha, Ariana Eunjung (28 Apr 2016). "There's a new sheriff in town in Silicon Valley — the FDA". The Washington Post. San Francisco, CA, USA. Retrieved 20 Oct 2019.
- ^ Terry, Mark (10 Sep 2018). "2 Bay Area Biotechs Launch IPOs Worth a Combined $200 Million". biospace.com. BioSpace. Retrieved 12 Nov 2019.
- ^ Fox, Michelle (4 Oct 2018). "Guardant Health soars almost 70% in first day of trading". CNBC. USA. Retrieved 12 Nov 2019.
- ^ a b Tansey, Burnadette (19 Sep 2014). "Forum Highlights Innovators Working in Global Public Interest". xconomy.com. Xconomy, Inc. Retrieved 24 Oct 2019.
- ^ Leuty, Ron (22 Jan 2015). "9 potential life science IPOs to watch". San Francisco Business Times. USA. Retrieved 25 Oct 2019.
- ^ Al Idius, Amirah (11 Dec 2017). "FierceMedTech's Fierce 15, 2017". Fiercebiotech.com. Questex, LLC.
- ^ a b c Sawers, Paul (11 May 2017). "Cancer screening firm Guardant Health raises US$360 million to sequence tumor DNA of 1 million patients". VentureBeat. USA. Retrieved 22 Oct 2019.
- ^ Regalado, Antonio (24 Jun 2015). "The Great Cancer Test Experiment". MIT Technology Review. MIT. Retrieved 12 Oct 2019.
- ^ a b Harper, Matthew (12 Nov 2018). "A $3 Billion Startup's Shares Gain On Hopes For A Cancer Blood Test". Forbes. Retrieved 11 Nov 2019.
- ^ a b O'Connor, Leo (9 Jan 2019). "JP Morgan Healthcare, Day 2: Thermo Fisher, Exact Sciences, Guardant, Hologic, Caris, and More". Retrieved 6 Nov 2019.
- ISBN 978-1-4903-3040-2. Retrieved 8 November 2019.
- ^ a b c Philippidis, Alex (27 Mar 2019). "Five-Year Super Successes in Genomics and Precision Medicine". ClinicalOmics. Retrieved 8 Nov 2019.
- ^ Teichert, Erica (20 Aug 2016). "Innovations: Startup's liquid biopsies match cancer patients with trials". Modern Healthcare. Crain Communications. Retrieved 22 Oct 2019.
- ^ "FDA Grants EAP Designation to Guardant's NGS-Based Liquid Biopsy". fdanews.com. FDA News. 22 Feb 2018. Retrieved 10 Nov 2019.
- ^ a b Philippidis, Alex (14 Jan 2019). "Guardant Health Launches Blood-Based Early Cancer Assay for Research Use". Genetic Engineering and Biotechnology News. Mary Ann Liebert. Retrieved 6 Nov 2019.
- ^ Baker, Liana; Roumeliotis, Greg (19 May 2017). "Dealmakers aplenty, SoftBank's Son looks for wonks". Reuters. Retrieved 25 Oct 2019.
- ^ Terry, Mark (28 Feb 2019). "Guardant Health's Liquid Biopsy Wins in Head-to-Head Trial in Lung Cancer". biospace.com. Retrieved 3 Oct 2019.
- ^ "Opening Bell, October 4, 2018: Ringing today's opening bells are Mateusz Morawiecki, Republic of Poland prime minister, at the NYSE, and Guardant Health with CEO Helmy Eltoukhy and President AmirAli Talasaz at the Nasdaq". CNBC. 4 Oct 2018. Retrieved 18 Oct 2019.
- ^ Hale, Connor. "Guardant's blood test tracks microsatellite instability status on par with tissue biopsy in new study". FierceBiotech. Quantex, LLC. Retrieved 25 Oct 2019.
- ^ "Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs". genomeweb.com. GenomeWeb. 13 Dec 2018. Retrieved 10 Nov 2019.
- ^ Lovelace, Berkeley Jr. (3 Jun 2019). "We're not far from using blood tests to detect early-stage cancer, says CEO of Silicon Valley oncology firm". CNBC. Retrieved 15 Oct 2019.
- ^ Columbus, Gina (24 Oct 2019). "Pivotal Study Examines Blood Test as CRC Screening Method". onclive.com. Intellisphere, LLC. Retrieved 12 Nov 2019.
- ^ "The Health Care 50: The 50 most influential people in health care (2018)". Time. 18 Oct 2018. Retrieved 25 Oct 2019.
- ^ "The Health Care 50: The 50 most influential people in health care (2018) - Helmy Eltoukhy and AmirAli Talasaz". Time. 18 Oct 2018. Retrieved 25 Oct 2019.
- ^ a b "Fortune's 40 under 40 (2017)". Fortune. 2017. Retrieved 22 Oct 2019.
- ^ a b "Fortune Magazine – Guardant Health CEO And President On This Year's "40 Under 40" List". califesciences.org. California Life Sciences Association. 2017. Retrieved 21 Oct 2019.
- S2CID 8813059. Retrieved 9 Nov 2019.
- S2CID 12890520.
- PMID 26474073.
- ^ US application 2009286299, Ronaghi, Mostafa; Eltoukhy, Helmy & Bazargan, Leila, "Engineered luciferases", published 2009-11-19
- The Board of Trustees of the Leland Stanford Junior University& inventors.
- ^ US 8236532, Ronaghi, Mostafa & Eltoukhy, Helmy, "Multibase delivery for long reads in sequencing by synthesis protocols", published 2012-08-07, assigned to Illumina, Inc. & inventors.
- ^ EP 3087204, Eltoukhy, Helmy & Talasaz, AmirAli, "Methods and systems for detecting genetic variants", published 2015-07-15, assigned to Guardant Health, Inc.
- ^ EP 2893040, Talasaz, AmirAli & Eltoukhy, Helmy, "Methods to detect rare mutations and copy number variation", published 2016-11-02, assigned to Guardant Health Inc.
- ^ US 9850523, Chudova, Darya; Eltoukhy, Helmy & Mortimer, Stefanie Ann Ward et al., "Methods for multi-resolution analysis of cell-free nucleic acids", published 2017-12-26, assigned to Guardant Health Inc.
- ^ "40 Under 40 Awards". evanta.us. eventa.us. 2019. Retrieved 25 Oct 2019.
- ^ "Convening Innovators from the Science and Technology Communities" (PDF). weforum.org. World Economic Forum. 2014. Retrieved 22 Oct 2019.
- ^ Mukhurjee, Sy (3 May 2017). "This Simple Cancer Test Comes With a Big Caveat". Fortune. Fortune Media IP Limited. Retrieved 22 Oct 2019.
- ^ "The Business of Personalized Medicine". personalizedmedicinesummit.com. BPM Summit. 2018. Retrieved 2 Oct 2019.
- ^ "Very Brief Blog: Bay Area "Business of Personalized Medicine Summit" - December 6, 2018". discoveriesinhealthpolicy.com. Discoveries in Health Policy: Ideas for or from an evolving healthcare system. 2018. Retrieved 6 Nov 2019.
- ^ "HLTH Announces First 150+ Senior Healthcare Executive Speakers, Including 100+ CEOs and Founders". thekennedyforum.org. The Kennedy Forum. 5 Oct 2017. Retrieved 5 Oct 2019.
- ^ "World Medical Innovation Forum 2016" (PDF). neuroscienceinnovationforum.org. World Medical Innovation Forum. 2016. Retrieved 3 Oct 2019.